{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:19:42Z","timestamp":1782944382847,"version":"3.54.5"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Despite limited paediatric approvals, the use of proton pump inhibitors (PPIs) among children has increased in recent years, and concerns have arisen about their safety, including the risk of allergies. To provide additional evidence on the paediatric safety of PPIs, we performed a study on suspected adverse drug reactions (ADRs) in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrieved from EudraVigilance reports of suspected ADRs for PPIs in the age class 0\u201311\u2009years in the period 2003\u20132022. Most reported ADRs and allergic conditions were evaluated by descriptive analysis. A case\u2010non\u2010case analysis was performed using reporting odds ratio (ROR) with a 95% confidence interval (CI). Chi\u2010square or Fisher's exact tests were used to detect differences in reporting rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1389 reports and 4157 suspected ADRs were analysed. Most reports involved omeprazole (46.9%) and esomeprazole (27.3%), and 75.8% concerned serious outcomes. Gastrointestinal disorders were among the most common suspected ADRs, with vomiting being the most frequently reported (2.3%). Among allergic conditions, there were six cases of toxic epidermal necrolysis, five of Stevens\u2013Johnson syndrome and four of drug reaction with eosinophilia and systemic symptoms. Statistically significant reactions for omeprazole were choking (ROR 5.54; 95% CI, 1.04\u201329.56) and pneumonia (3.61; 1.41\u20139.20), while for esomeprazole gastrointestinal disorder (7.57; 1.18\u201348.60) and constipation (4.74; 2.25\u20139.98).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most common suspected ADRs reported with paediatric PPI use in Europe were gastrointestinal disorders, consistent with the safety profile in the product license. However, a high proportion of serious ADRs and few cases of severe cutaneous adverse reactions were reported.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/fcp.70036","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T22:12:46Z","timestamp":1751926366000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety of Proton Pump Inhibitor in Paediatrics: A Study Based on EudraVigilance Data"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7897-2956","authenticated-orcid":false,"given":"Greta","family":"Santi\u00a0Laurini","sequence":"first","affiliation":[{"name":"Unit of Pharmacology, Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-3043","authenticated-orcid":false,"given":"Victoria","family":"Nikitina","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology, Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5710-8077","authenticated-orcid":false,"given":"Nicola","family":"Montanaro","sequence":"additional","affiliation":[{"name":"Pharmacology at the Alma Mater Studiorum University di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-4014","authenticated-orcid":false,"given":"Domenico","family":"Motola","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology, Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"European Medicines Agency \u201cReport on the Survey of All Paediatric Uses of Medicinal Products in Europe \u201d accessed June 30 2023 https:\/\/www.ema.europa.eu\/en\/documents\/report\/report\u2010survey\u2010all\u2010paediatric\u2010uses\u2010medicinal\u2010products\u2010europe_en.pdf."},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3182a3b04e"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13191"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1052978"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31812e0149"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551\u20106776\u201019.4.283"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001596"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild\u20102017\u2010314161"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41390\u2010021\u201001821\u2010y"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010\u20102719"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004\u20102803.201700000\u201042"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000188008.66752.72"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31823890b4"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000968"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.839972"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.0315"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.5710"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.07.013"},{"key":"e_1_2_13_20_1","unstructured":"\u201cEudravigilance\u2014European Database of Suspected Adverse Drug Reaction Reports \u201d accessed May 22 2023 https:\/\/www.adrreports.eu\/."},{"key":"e_1_2_13_21_1","unstructured":"European Medicines Agency \u201cEudraVigilance \u201d accessed May 22 2023 https:\/\/www.ema.europa.eu\/en\/human\u2010regulatory\/research\u2010development\/pharmacovigilance\/eudravigilance."},{"key":"e_1_2_13_22_1","unstructured":"European Medicines Agency \u201cICH E11(R1) Guideline on Clinical Investigation of Medicinal Products in the Pediatric Population \u201d accessed July 4 2023 https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010e11r1\u2010guideline\u2010clinical\u2010investigation\u2010medicinal\u2010products\u2010pediatric\u2010population\u2010revision\u20101_en.pdf."},{"key":"e_1_2_13_23_1","unstructured":"European Medicines Agency \u201cGuideline on Good Pharmacovigilance Practices (GVP) Module VI\u2014Collection Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products (Rev 2) \u201d accessed July 4 2023 https:\/\/www.ema.europa.eu\/en\/documents\/regulatory\u2010procedural\u2010guideline\/guideline\u2010good\u2010pharmacovigilance\u2010practices\u2010gvp\u2010module\u2010vi\u2010collection\u2010management\u2010submission\u2010reports_en.pdf."},{"key":"e_1_2_13_24_1","unstructured":"MedDRA \u201cMedical Dictionary for Regulatory Activities \u201d accessed July 4 2023 https:\/\/www.meddra.org\/how\u2010to\u2010use\/support\u2010documentation\/english\/welcome."},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010199920020\u201000002"},{"key":"e_1_2_13_26_1","volume-title":"Side Effects Drugs Annual","author":"Harrison J.","year":"2009"},{"key":"e_1_2_13_27_1","unstructured":"Takeda \u201cDexilant\u00ae 30 mg\/60 mg Hartkapseln mit ver\u00e4nderter Wirkstofffreisetzung \u201d accessed September 6 2023 https:\/\/www.takeda\u2010produkte.de\/system\/files\/produkt\u2010info\/fachinformation\u2010dexilantr.pdf."},{"key":"e_1_2_13_28_1","unstructured":"European Medicines Agency \u201cLasoprazol\u2010Ratiopharm INN\u2010Lansoprazole \u201d accessed September 6 2023 https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lansoprazol\u2010ratiopharm\u201015\u2010mg\u201030\u2010mg\u2010article\u201029\u2010referral\u2010annex\u2010i\u2010ii\u2010iii_en.pdf."},{"key":"e_1_2_13_29_1","unstructured":"Agenzia Italiana del Farmaco \u201cNexium\u00ae Riassunto delle caratteristiche del prodotto \u201d accessed September 6 2023 https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_001429_034972_RCP.pdf&retry=0&sys=m0b1l3."},{"key":"e_1_2_13_30_1","unstructured":"Takeda \u201cPantoprazol NYC 40 mg magensaftresistente Tabletten \u201d accessed September 6 2023 https:\/\/www.takeda\u2010produkte.de\/system\/files\/produkt\u2010info\/fachinformation\u2010pantoprazol\u2010nycr\u201040\u2010mg\u2010magensaftresistente\u2010tabletten.pdf."},{"key":"e_1_2_13_31_1","unstructured":"Agenzia Italiana del Farmaco \u201cPariet\u00ae Riassunto delle caratteristiche del prodotto \u201d accessed September 6 2023 https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_001445_034216_RCP.pdf&sys=m0b1l3."},{"key":"e_1_2_13_32_1","unstructured":"European Medicines Agency \u201cLosec\u2014Annex III Summary of Product Characteristics Labelling and Package Leaflet \u201d accessed September 6 2023 https:\/\/www.ema.europa.eu\/en\/documents\/referral\/losec\u2010article\u201030\u2010referrals\u2010annex\u2010iii_en.pdf."},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15213"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272\u2010013\u20100012\u2010x"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12619"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v7.i4.531"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.01.004"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1978975"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild\u20102017\u2010314026"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2023.2900"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005\u20101655"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001984"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03229\u20102020"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102022\u2010060771"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398\u20109995.2010.02511.x"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.832048"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12034"},{"key":"e_1_2_13_48_1","unstructured":"European Medicines Agency \u201cGuideline on Good Pharmacovigilance Practices (GVP) Product\u2010 or Population\u2010Specific Considerations IV: Paediatric Population \u201d accessed October 17 2023 https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010good\u2010pharmacovigilance\u2010practices\u2010gvp\u2010product\u2010or\u2010population\u2010specific\u2010considerations\u2010iv\u2010paediatric\u2010population_en.pdf."},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2015.0781"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.21037\/tp\u201022\u2010401"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010368"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:33:56Z","timestamp":1764509636000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.70036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/fcp.70036"],"URL":"https:\/\/doi.org\/10.1111\/fcp.70036","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"2025-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70036"}}